Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TXP1-oligoMAPT
- Development stage
- Preclinical
- Lead developer
- Ossianix
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
TXP1-oligoMAPT is a preclinical-stage brain shuttle-enabled small interfering RNA (siRNA) conjugate developed by Ossianix for the treatment of Alzheimer's disease and other tauopathies. The therapeutic consists of TXP1, a novel brain shuttle based on a single-domain Variable New Antigen Receptor (VNAR) anti-transferrin receptor 1 (TfR1) antibody derived from shark antibodies, site-specifically conjugated to an siRNA targeting microtubule-associated protein tau (MAPT). By targeting TfR1, TXP1 facilitates receptor-mediated transcytosis across the blood-brain barrier (BBB) to deliver the siRNA payload into the central nervous system, where it silences MAPT expression to reduce tau protein levels and mitigate tau pathology.
02
Targets
RISC (RNA-induced silencing complex)MAPT (Microtubule-associated protein tau)TFRC (Transferrin Receptor)
Beyond the preview
Go deeper on TXP1-oligoMAPT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TXP1-oligoMAPT.